Cipla Ltd.

Financial

	Cipla	Torrent Pharma	Mankind Pharma
Operational Metrics
Pharmaceutical Sector
Number of ANDA's Filed in USA	282.0 .	172.0 .	67.0 .
Number of ANDA's Approved By USFDA	217.0 .	132.0 .	48.0 .
Domestic Sales Growth - YoY	6.8 %	12.3 %	7.9 %
US DMF Filings	2472.0 .	n/a	n/a
R&D as a % of Total Sales	6.2 %	5.0 %	2.2 %
Financials
5 yr Average ROE	13.9 %	20.79 %	20.33 %
5yr average Equity Multiplier	1.25	2.16	1.46
5yr Average Asset Turnover Ratio	0.78	0.69	0.81
5yr Avg Net Profit Margin	14.31 %	13.95 %	17.68 %
Price to Book	3.89	16.38	7.38
P/E	22.49	62.11	55.87
5yr Avg Cash Conversion Cycle	-4.31 Days	-186.79 Days	-13.08 Days
Inventory Days	57.83 Days	54.98 Days	59.06 Days
Days Receivable	50.64 Days	40.18 Days	34.35 Days
Days Payable	105.99 Days	298.32 Days	121.69 Days
5yr Average Interest Coverage Ratio	53.73	7.38	46.07
5yr Avg ROCE	19.36 %	25.78 %	25.06 %
5yr Avg Operating Profit Margin	23.02 %	30.49 %	24.62 %
5 yr average Debt to Equity	0.03	0.66	0.16
5yr CAGR Net Profit	17.0 %	8.83 %	9.49 %
5yr Average Return on Assets	11.19 %	9.73 %	14.46 %
Shareholdings
Promoter Holding	29.19 %	68.31 %	72.68 %
Share Pledged by Promoters	0.0	0.0	0.0
Change in Promoter Holding (3 Yrs)	-4.42 %	-2.94 %	-3.82 %
Change in Mutual Fund Holding (3 Yrs)	7.05 %	-2.83 %	5.51 %

Business

	Cipla	Torrent Pharma	Mankind Pharma
Product Wise Break-Up	Product Wise Break-Up Pharmaceutical 93.68 New ventures 6.32 US Formulations 0 Domestic formulations 0 Contract Manf. 0 Brazil/Latam 0 Germany/Europe 0 Urology 0 Neuro/CNS 0 Pain/Analgesics 0 Gynaecology 0 Dermatology 0 Anti-Diabetic 0 Respiratory 0 VMN 0 Gastro - Intestinal 0 Cardiovascular 0 Anti-infectives 0	Product Wise Break-Up Brazil 8.98 Gynaecology 0 Dermatology 0 VMN 0 US Formulations 20.71 New ventures 0 Germany 13.15 Domestic Formulations 42.15 Neuro/CNS 0 Cardiovascular 0 Anti-Diabetic 0 Gastro - Intestinal 0 Urology 0 Anti-infectives 0 Respiratory 0 Contract Manufacturing 6.15 Pharmaceutical 0 Pain/Analgesics 0 Others 8.86	Product Wise Break-Up Brazil/Latam 0 Gynaecology 13.0 Dermatology 5.0 VMN 7.0 US Formulations 0 New ventures 0 Germany/Europe 0 Domestic formulations 0 Neuro/CNS 5.0 Cardiovascular 13.0 Anti-Diabetic 8.0 Gastrointestinal 11.0 Urology 5.0 Anti-infectives 16.0 Respiratory 8.0 Contract Manf. 0 Pharmaceutical 0 Pain/Analgesics 4.0 Others 5.0
Therapeutic Area Wise Break-Up - Domestic	Therapeutic Area Wise Break-Up - Domestic Respiratory Systems 36.4 Anti-Infective 13.8 Cardiac Science 11.8 Gastro Intestinal 5.5 Anti - Diabetes 5.5 Urology 5.1 Central Nervous System (CNS) 4.5 Pain Management 4.3 Derma 3.5 Ophthalmology 2.6 Antivirals 0 Gynaec. 0 Vitamins 0 Antineoplast 0 Oncology 0 Others 7.0	-	-
Location Wise Break-Up	Location Wise Break-Up India 44.0 North America 28.0 SAGA 13.0 Europe 12.0 Global API 1.0 Rest of the World 0 Emerging Markets 0 Germany 0 USA 0 Brazil 0 Nepal 0 Sri Lanka 0 Bangladesh 0 Others 2.0	Location Wise Break-Up North America 0 Emerging Markets 0 Global API 0 Brazil 6.86 India 56.99 SAGA 0 USA 9.69 Nepal 0 Bangladesh 0 Sri Lanka 0 Germany 9.69 Rest of the World 0 Europe 0 Others 16.77	Location Wise Break-Up North America 0 Emerging Markets 0 Global API 0 Brazil 0 India 83.0 SAGA 0 USA 0 Nepal 0 Bangladesh 0 Sri Lanka 0 Germany 0 Rest of the World 0 Europe 0 Others 17.0
Operating Profit Break-Up	Operating Profit Break-Up Pharmaceuticals 96.82 New Ventures 3.18	-	-
Asset Break-Up	Asset Break-Up India 49.7 USA 28.99 South Africa 18.03 Others 3.28	Asset Break-Up USA 0.46 South Africa 0 India 94.39 Others 5.15	-

Cipla Ltd.

SIGN UP FOR FREE